---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-040217"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:54:36.193279+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q1 net loss $14.6M ($0.97/sh) vs $3.5M loss YoY; cash $24.3M from $30M upfront financing

## Summary
- Net loss of $14.6M ($0.97/sh) compared to $3.5M ($0.24/sh) in Q1 2022; includes $10.4M change in warrant liability.
- Licensing revenue $0.7M from Lotus Pharma agreement for Renazorb in South Korea signed February 2023.
- Cash and cash equivalents $24.3M (Dec 2022: $0.5M) after $30M upfront from up to $130M private placement.
- Plans to file NDA for Renazorb by Q3 2023 with potential approval and launch in 2024.
- UNI-494 Phase 1 first cohort enrolled; plans to file IND in 2024 for Phase 2 trial in AKI.

## SEC filing metadata
- accession: 0001213900-23-040217
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/0001213900-23-040217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/ea178564-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-040217
- JSON: https://secwatch.observer/filing/0001213900-23-040217.json
- Plain text: https://secwatch.observer/filing/0001213900-23-040217.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.7 million, net income $14.6 million, EPS $0.97 per share of common stock.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $0.7 million
  - Net income: $14.6 million
  - EPS: $0.97 per share of common stock
  - Result: reported results
  source text: Renal Association Congress (ERA 2023) taking place in Milan, Italy from June 15-18, 2023. Financial Results for the First Quarter Ended March 31, 2023 Licensing revenues were $0.7 million for the quarter ended March 31, 2023 due to a licensing agreement executed in February 2023. Research and development expenses for the quarter ended March 31, 2023 were $3.0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/0001213900-23-040217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.